Ascentage Pharma Group International
Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on discovering, developing, and commercializing therapies for cancers, chronic hepatitis B virus, and age-related diseases. Its current portfolio centers on novel small-molecule drugs designed to regulate programmed cell death pathways, with emphasis on hematologic malignancies and other oncology indications. The company’s development pipeline includes product candidates such as olverembatinib, a BCR-ABL inhibitor, along with additional therapies targeting apoptosis-related pathways and other cancer-relevant mechanisms. Ascentage Pharma Group International operates as an integrated biopharmaceutical business, supporting research, clinical development, and commercialization activities across major markets including Mainland China and the United States. Headquartered in Suzhou, China, the company plays a specialized role in the global biotechnology sector by advancing targeted treatment options for diseases with significant unmet medical needs.
WebsiteCompany Information
Location
Suzhou Industrial Park
Suzhou, 215000
China